Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. (Q47874565)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Roberto Iacovelli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Matteo Santoni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

F Massari

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Cristina Masini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Melissa Bersanelli

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Carlo Terrone

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

13

Cristian Lolli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

15

Rossana Berardi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

4

Ugo De Giorgi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

22

Giampaolo Tortora

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

3

Luca Galli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

8

Giuseppe Fornarini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

7

Alessandra Mosca

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

21

Franco Nolè

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

5

Roberto Sabbatini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

18

Andrea Ardizzoni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Maria Cossu Rocca

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Elisa Biasco

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Annalisa Guida

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Alessandro Pastorino

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Carmine Pinto

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

29 May 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

541.e7-541.e13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

Clinical biomarkers of response in advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.05.007

10.1016/J.UROLONC.2017.05.007

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28572027%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference